

# Cancer Risk in Patients with Rheumatoid Arthritis Receiving bDMARDs and tsDMARDs: Data from a Multicenter National Real-World Registry

**Juan Molina-Collada**<sup>1</sup>, Lucía Otero-Varela<sup>2</sup>, Paloma Vela Casasempere<sup>3</sup>, Sara Manrique-Arija<sup>4</sup>, Celia Erasquin<sup>5</sup>, Cristina Campos Fernández<sup>6</sup>, Francisco Javier Manero Ruiz<sup>7</sup>, Jerusalem Calvo-Gutiérrez<sup>8</sup>, Lorena Expósito<sup>9</sup>, Javier García-González<sup>10</sup>, Dolores Ruiz-Montesino<sup>11</sup>, Elena Rabadan<sup>12</sup>, Antonio Jose Mera-Varela<sup>13</sup>, Inmaculada Ros<sup>14</sup>, María Colazo-Burlato<sup>15</sup>, Chamaida Plasencia-Rodríguez<sup>16</sup>, Fernando Sánchez-Alonso<sup>2</sup>, Isabel Castrejon<sup>1</sup>, on behalf of BIOBADASER Project Collaborative Group

<sup>1</sup>Department of Rheumatology, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, <sup>2</sup>Unidad de investigación, Sociedad Española de Reumatología, Madrid, Spain, <sup>3</sup>Department of Rheumatology, Hospital General Universitario de Alicante Doctor Balmis, Alicante, Spain, <sup>4</sup>Department of Rheumatology, Hospital Regional Universitario de Málaga, Málaga, Spain, <sup>5</sup>Department of Rheumatology, Hospital Universitario de Gran Canaria Doctor Negrín, Gran Canaria, Spain, <sup>6</sup>Department of Rheumatology, Consorcio Hospital General Universitario de Valencia, Valencia, Spain, <sup>7</sup>Department of Rheumatology, Hospital Universitario Miguel Servet, Zaragoza, Spain, <sup>8</sup>Department of Rheumatology, Hospital Universitario Reina Sofía, Córdoba, Spain, <sup>9</sup>Department of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain, <sup>10</sup>Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, <sup>11</sup>Department of Rheumatology, Hospital Universitario Virgen Macarena, Sevilla, Spain, <sup>12</sup>Department of Rheumatology, Hospital Universitario Príncipe de Asturias, Madrid, Spain, <sup>13</sup>Department of Rheumatology, Hospital Clínico Universitario de Santiago, Santiago de Compostela, A Coruña, Spain, <sup>14</sup>Department of Rheumatology, Hospital Universitario Son Llatzer, Palma de Mallorca, Spain, <sup>15</sup>Department of Rheumatology, Hospital Universitario de Burgos, Burgos, Spain, <sup>16</sup>Department of Rheumatology, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain

## Objective

- To evaluate the risk of cancer in patients with RA receiving bDMARDs and tsDMARDs.


## Methods

- Prospective cohort study from a multicenter national registry of targeted therapies, including RA patients treated with bDMARDs or tsDMARDs from 2000 to 2023.
- Patients with prior cancer were excluded from the analysis.
- Incidence rates (IR) were analysed, and adjusted and stratified Cox regression was used to estimate hazard ratios (HR) for all cancers excluding non-melanoma skin cancer (NMSC) and for NMSC.
- Treatment with TNFi was used as the reference for comparison.

	TNFi	IL6i	CD20i	JAKi	CTLA4-A	Total
Patients, n	3034	1106	476	1320	906	4635
Demographics						
Female, n (%)	2410 (79.4)	905 (81.8)	377 (79.2)	1079 (81.7)	678 (74.8)	3662 (79.0)
Age at disease onset, mean (SD)	54.3 (12.3)	56.9 (12.4)	57.2 (11.6)	56.0 (12.0)	60.8 (12.1)	55.5 (12.4)
Disease duration, median [IQR]	5.7 [2.2 - 11.3]	9.1 [4.3 - 15.4]	10.7 [5.6 - 16.9]	9.5 [4.0 - 16.0]	9.5 [4.7 - 16.7]	6.5 [2.5-12.8]
Follow-up time (years), median [IQR]	3.4 [1.6- 6.7]	4.0 [2.0- 7.0]	5.2 [2.3- 8.3]	2.6 [1.5 - 4.3]	3.7 [1.7- 6.4]	3.6 [1.7-6.3]
Comorbidities						
Charlson, median [IQR]	1.0 [1.0- 1.0]	1.0 [1.0- 1.0]	1.0 [1.0- 1.0]	1.0 [1.0 - 1.0]	1.0 [1.0- 1.0]	1.0 [1.0 - 1.0]
Obesity, n (%)	634 (20.9)	238 (21.5)	84 (17.7)	281 (21.3)	218 (24.1)	1012 (21.8)
Smoker, n (%)	569 (18.8)	201 (18.2)	91 (19.1)	242 (18.3)	154 (17.0)	836 (18.0)
Previous CVD*	377 (12.4)	150 (13.6)	61 (12.8)	185 (14.0)	165 (18.2)	655 (14.1)
* At least one of the following: hyperlipidaemia, diabetes, myocardial infarction, stroke, congestive heart failure, ischemic heart disease, peripheral vascular disease						

**Table 1.** Baseline characteristics of patients with rheumatoid arthritis included in the multicenter national registry, based on type of treatment.

## Results



**Figure 1.** Cancer risk excluding NMSC (A) and NMSC risk (B) (overall, stratified by cardiovascular risk and by line of treatment) in RA patients receiving targeted therapies included in BIOBADASER.

## Conclusions

- Based on the treatment patterns for RA patients observed in our real-world registry, we have not identified an increased cancer risk for any of the bDMARDs or tsDMARDs, in comparison to TNFi.